Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 213

1.

HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.

Gajria D, Chandarlapaty S.

Expert Rev Anticancer Ther. 2011 Feb;11(2):263-75. doi: 10.1586/era.10.226. Review.

2.

A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.

Elster N, Cremona M, Morgan C, Toomey S, Carr A, O'Grady A, Hennessy BT, Eustace AJ.

Breast Cancer Res Treat. 2015 Jan;149(2):373-83. doi: 10.1007/s10549-014-3239-5. Epub 2014 Dec 21.

PMID:
25528022
3.

Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.

Nahta R, O'Regan RM.

Clin Breast Cancer. 2010 Nov;10 Suppl 3:S72-8. doi: 10.3816/CBC.2010.s.015. Review.

PMID:
21115425
4.

Novel targeted therapies to overcome trastuzumab resistance in HER2-overexpressing metastatic breast cancer.

Huang Y, Fu P, Fan W.

Curr Drug Targets. 2013 Jul;14(8):889-98. Review.

PMID:
23531110
5.

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.

Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ.

Nat Clin Pract Oncol. 2006 May;3(5):269-80. Review.

PMID:
16683005
6.

Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.

Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, Corominas-Faja B, Urruticoechea A, Martin-Castillo B, Menendez JA.

Oncotarget. 2012 Dec;3(12):1600-14.

7.

Beyond trastuzumab and lapatinib: new options for HER2-positive breast cancer .

Zardavas D, Cameron D, Krop I, Piccart M.

Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e2. Review.

8.

A systematic review of dual targeting in HER2-positive breast cancer.

Kümler I, Tuxen MK, Nielsen DL.

Cancer Treat Rev. 2014 Mar;40(2):259-70. doi: 10.1016/j.ctrv.2013.09.002. Epub 2013 Sep 11. Review.

PMID:
24080156
9.

Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.

Yao E, Zhou W, Lee-Hoeflich ST, Truong T, Haverty PM, Eastham-Anderson J, Lewin-Koh N, Gunter B, Belvin M, Murray LJ, Friedman LS, Sliwkowski MX, Hoeflich KP.

Clin Cancer Res. 2009 Jun 15;15(12):4147-56. doi: 10.1158/1078-0432.CCR-08-2814. Epub 2009 Jun 9.

10.

Her2 cross talk and therapeutic resistance in breast cancer.

Bender LM, Nahta R.

Front Biosci. 2008 May 1;13:3906-12. Review.

11.

[Trastuzumab (Herceptin) and breast cancer: mechanisms of resistance].

Dieras V, Vincent-Salomon A, Degeorges A, Beuzeboc P, Mignot L, de Cremoux P.

Bull Cancer. 2007 Mar;94(3):259-66. Review. French.

12.
13.

Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.

Spector NL, Blackwell KL.

J Clin Oncol. 2009 Dec 1;27(34):5838-47. doi: 10.1200/JCO.2009.22.1507. Epub 2009 Nov 2. Review.

PMID:
19884552
14.

Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer.

Chandarlapaty S, Sakr RA, Giri D, Patil S, Heguy A, Morrow M, Modi S, Norton L, Rosen N, Hudis C, King TA.

Clin Cancer Res. 2012 Dec 15;18(24):6784-91. doi: 10.1158/1078-0432.CCR-12-1785. Epub 2012 Oct 23.

15.

Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines.

Kataoka Y, Mukohara T, Shimada H, Saijo N, Hirai M, Minami H.

Ann Oncol. 2010 Feb;21(2):255-62. doi: 10.1093/annonc/mdp304. Epub 2009 Jul 24.

PMID:
19633047
16.

PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling.

Moody SE, Schinzel AC, Singh S, Izzo F, Strickland MR, Luo L, Thomas SR, Boehm JS, Kim SY, Wang ZC, Hahn WC.

Oncogene. 2015 Apr 16;34(16):2061-71. doi: 10.1038/onc.2014.153. Epub 2014 Jun 9.

17.

New therapies in HER2-positive breast cancer: a major step towards a cure of the disease?

Awada A, Bozovic-Spasojevic I, Chow L.

Cancer Treat Rev. 2012 Aug;38(5):494-504. doi: 10.1016/j.ctrv.2012.01.001. Epub 2012 Feb 3. Review.

PMID:
22305205
18.

Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT.

O'Brien NA, McDonald K, Tong L, von Euw E, Kalous O, Conklin D, Hurvitz SA, di Tomaso E, Schnell C, Linnartz R, Finn RS, Hirawat S, Slamon DJ.

Clin Cancer Res. 2014 Jul 1;20(13):3507-20. doi: 10.1158/1078-0432.CCR-13-2769. Epub 2014 May 30.

19.

Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.

Esteva FJ, Pusztai L.

Oncology (Williston Park). 2005 Nov;19(13 Suppl 5):5-16. Review.

20.

Treatment of HER2-positive metastatic breast cancer following initial progression.

Mayer IA.

Clin Breast Cancer. 2009 Jun;9 Suppl 2:S50-7. doi: 10.3816/CBC.2009.s.005. Review.

Supplemental Content

Support Center